Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ascendis Pharma ASASND +0.53%41 Days Sales Outstanding is 51.88 as of Jun. 2026, which is at its 10-year median of 51.88. GuruFocus rates ASND with a GF Score™ of 41/100. The stock has 3 warning signs investors should review. Among 841 Biotechnology companies, Ascendis Pharma AS ranks better than 62.07% on this metric.
Ascendis Pharma AS (NAS:ASND) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Ascendis Pharma AS Days Sales Outstanding Related Terms
Ascendis Pharma AS Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Ascendis Pharma AS's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASND vs JAZZ, BBIO, EXEL: Days Sales Outstanding Comparison
For the Biotechnology subindustry, Ascendis Pharma AS's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ascendis Pharma AS Days Sales Outstanding vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ascendis Pharma AS's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Ascendis Pharma AS's Days Sales Outstanding falls into.
Ascendis Pharma AS Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ascendis Pharma AS (ASND) has a Days Sales Outstanding of 51.88 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Ascendis Pharma AS and its competitors. This is near median its historical median of 51.88. Over the past decade, Ascendis Pharma AS's Days Sales Outstanding has ranged from 3.47 to 102.20. According to the industry distribution chart, Ascendis Pharma AS ranks #319 out of 841 companies in the Biotechnology industry, placing it in the top 37.9%.
Is Ascendis Pharma AS's Days Sales Outstanding too high?
Ascendis Pharma AS's current Days Sales Outstanding of 51.88 is near median its 10-year median of 51.88. Over the past 10 years, this metric has ranged from a low of 3.47 to a high of 102.20. The Biotechnology industry median Days Sales Outstanding is 68.98. Ascendis Pharma AS's value of 51.88 is 24.8% below this industry median. Based on the distribution chart, Ascendis Pharma AS ranks #319 out of 841 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Ascendis Pharma AS has a GF Score™ of 41/100, reflecting its overall financial health beyond just this single metric.
How does Ascendis Pharma AS's Days Sales Outstanding compare to JAZZ and BBIO?
According to the Biotechnology industry distribution chart, Ascendis Pharma AS ranks #319 out of 841 companies for Days Sales Outstanding. This puts Ascendis Pharma AS in the upper half of its industry. The industry median Days Sales Outstanding is 68.98. Ascendis Pharma AS's value of 51.88 is 24.8% below this benchmark. Historically, Ascendis Pharma AS's own Days Sales Outstanding has ranged from 3.47 to 102.20 over the past decade. While the company's 10-year median is 51.88 vs. the industry median of 68.98, Ascendis Pharma AS has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Biotechnology company?
The median Days Sales Outstanding among Biotechnology companies is 68.98, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ascendis Pharma AS's current Days Sales Outstanding of 51.88 is 24.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Ascendis Pharma AS and its competitors. For the Biotechnology industry, the median Days Sales Outstanding is 68.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ascendis Pharma AS's current Days Sales Outstanding is 51.88, which is near median its own 10-year median of 51.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ascendis Pharma AS stock overvalued right now?
Ascendis Pharma AS (ASND) has a current Days Sales Outstanding of 51.88. The current Days Sales Outstanding is 51.88, which is near median its 10-year median of 51.88 and 24.8% below the Biotechnology industry median of 68.98. Ascendis Pharma AS's overall GF Score™ is 41/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Ascendis Pharma AS (ASND), the current Days Sales Outstanding is 51.88 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.
41GF Score
Get the complete analysis for ASND
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASND has been successfully added to your 
